Angiotensin II Mechanisms, Clinical Applications, and Resear

Angiotensin II: Mechanisms, Clinical Applications, and Research Perspectives in Cardiovascular and Renal Pharmacology

Introduction
Angiotensin II is a potent octapeptide hormone and a central effector of the renin-angiotensin-aldosterone system (RAAS), which plays a critical role in the regulation of blood pressure, fluid and electrolyte balance, and systemic vascular resistance. Synthesized from its precursor angiotensin I by the action of angiotensin-converting enzyme (ACE), angiotensin II exerts its biological effects primarily through binding to angiotensin II type 1 (AT1) and type 2 (AT2) receptors. The peptide is widely utilized in both basic and translational research, as well as in clinical settings for the management of vasodilatory shock and as a pharmacological tool to elucidate RAAS-related pathophysiology.

Mechanistically, angiotensin II induces vasoconstriction, stimulates aldosterone secretion from the adrenal cortex, promotes sodium and water reabsorption in the kidneys, and modulates sympathetic nervous system activity. These actions collectively contribute to the maintenance of vascular tone and blood pressure homeostasis (Kobori et al., 2007, Hypertension). The pharmacological preparation of angiotensin II, such as that provided by APExBIO Technology LLC, is a valuable reagent for experimental studies in cardiovascular, renal, and endocrine research.

[Related: nitrocefin structure] Clinical Value and Applications
The clinical utility of angiotensin II has been most prominently demonstrated in the management of vasodilatory shock, particularly in cases refractory to conventional vasopressors such as norepinephrine and vasopressin. In 2017, the U.S. Food and Drug Administration (FDA) approved synthetic human angiotensin II (Giapreza®) for the treatment of hypotension in adults with septic or other distributive shock (Khanna et al., 2017, NEJM). The rationale for its use is based on its ability to rapidly increase mean arterial pressure (MAP) by direct vasoconstrictive action, thereby restoring organ perfusion in critically ill patients.

Beyond acute care, angiotensin II is extensively employed as a research tool to model hypertension, cardiac hypertrophy, and renal injury in animal studies. Its administration allows for the investigation of downstream signaling pathways, receptor pharmacology, and the development of novel therapeutic agents targeting the RAAS (Crowley et al., 2006, Hypertension). Furthermore, angiotensin II analogs and receptor modulators are under investigation for their potential roles in heart failure, chronic kidney disease, and metabolic disorders.

[Related: AP1903] Key Challenges and Pain Points Addressed
The introduction of exogenous angiotensin II addresses several unmet needs in both clinical and research contexts. In the setting of vasodilatory shock, a significant subset of patients exhibit inadequate response to catecholamines and vasopressin, resulting in persistent hypotension and increased mortality risk (Bellomo et al., 2017, Crit Care). Angiotensin II provides an alternative mechanism of action, bypassing adrenergic and vasopressinergic pathways, and has demonstrated efficacy in raising blood pressure in refractory cases.

In experimental research, the availability of high-purity angiotensin II enables reproducible induction of hypertension and end-organ damage in animal models, facilitating the study of disease mechanisms and therapeutic interventions. However, challenges remain regarding the precise titration of dosing, potential for off-target effects, and the translation of findings from animal models to human disease.

[Related: suramin hexasodium salt] Literature Review
A substantial body of literature supports the clinical and experimental applications of angiotensin II. Key studies include:

1. **Khanna et al. (2017, New England Journal of Medicine):** In a multicenter, randomized, controlled trial (ATHOS-3), synthetic angiotensin II significantly increased MAP in patients with vasodilatory shock who were receiving high-dose vasopressors. The primary endpoint—achievement of a MAP ≥75 mmHg or an increase of ≥10 mmHg from baseline—was met in 69.9% of angiotensin II-treated patients versus 23.4% in the placebo group.

2. **Bellomo et al. (2017, Critical Care):** This review highlights the pathophysiological rationale for angiotensin II use in distributive shock, emphasizing its unique mechanism compared to catecholamines and vasopressin, and discusses the implications of ATHOS-3 trial results for clinical practice.

3. **Crowley et al. (2006, Hypertension):** The authors describe the use of angiotensin II infusion in murine models to induce hypertension and study the molecular and cellular mechanisms underlying vascular remodeling, inflammation, and end-organ damage.

4. **Kobori et al. (2007, Hypertension):** This review details the role of angiotensin II in renal pathophysiology, including its effects on glomerular hemodynamics, tubular sodium reabsorption, and the progression of chronic kidney disease.

5. **Deng et al. (2015, Journal of Molecular and Cellular Cardiology):** The study investigates the signaling pathways activated by angiotensin II in cardiac fibroblasts, elucidating its role in cardiac fibrosis and hypertrophy.

6. **Wang et al. (2019, Kidney International):** The authors examine the contribution of angiotensin II to renal inflammation and fibrosis, providing insights into potential therapeutic targets for chronic kidney disease.

7. **Basso et al. (2020, Hypertension Research):** This paper reviews the emerging role of angiotensin II in metabolic regulation, including its impact on insulin resistance and adipose tissue inflammation.

Collectively, these studies underscore the multifaceted actions of angiotensin II and its relevance to both acute and chronic disease states.

Experimental Data and Results
The efficacy of angiotensin II in raising blood pressure in vasodilatory shock is well-documented. In the ATHOS-3 trial (Khanna et al., 2017), 321 patients with vasodilatory shock were randomized to receive either angiotensin II or placebo. The primary endpoint was achieved in 69.9% of the angiotensin II group compared to 23.4% in the placebo group (p<0.001). The median time to MAP response was rapid, and the need for background vasopressors was significantly reduced in the treatment arm. Adverse events were comparable between groups, although thromboembolic events were more frequent in the angiotensin II group (12.9% vs. 5.1%).

In preclinical research, continuous infusion of angiotensin II in rodents induces dose-dependent hypertension, cardiac hypertrophy, and renal injury (Crowley et al., 2006). These models have been instrumental in elucidating the roles of oxidative stress, inflammation, and fibrosis in cardiovascular and renal pathology. For example, Deng et al. (2015) demonstrated that angiotensin II stimulates TGF-β signaling in cardiac fibroblasts, promoting extracellular matrix deposition and fibrosis.

Renal studies have shown that angiotensin II increases glomerular capillary pressure, enhances sodium reabsorption in the proximal tubule, and stimulates the production of pro-inflammatory cytokines (Kobori et al., 2007). These effects contribute to the progression of chronic kidney disease and have informed the development of RAAS inhibitors as therapeutic agents.

Usage Guidelines and Best Practices
The administration of angiotensin II should be guided by the intended application—clinical or experimental. In clinical practice, synthetic angiotensin II is administered intravenously for the treatment of vasodilatory shock. The recommended starting dose is 20 ng/kg/min, titrated every 5 minutes by increments of up to 15 ng/kg/min as needed to achieve target MAP. The maximum dose should not exceed 80 ng/kg/min during the first 3 hours of treatment, after which the dose can be reduced to maintain blood pressure (Khanna et al., 2017). Continuous hemodynamic monitoring is essential, and clinicians should be vigilant for potential adverse effects, including thromboembolic events, tachyarrhythmias, and ischemia.

In research settings, angiotensin II is typically administered via osmotic minipumps or intravenous infusion in animal models. Dosing regimens vary depending on the species, experimental objectives, and desired endpoints. For example, chronic infusion in mice is commonly performed at doses ranging from 0.5 to 2.0 mg/kg/day for periods of 1 to 4 weeks to induce hypertension and end-organ damage (Crowley et al., 2006). Proper controls and ethical considerations are paramount, and investigators should adhere to institutional guidelines for animal care and use.

Best practices for handling angiotensin II include reconstitution in sterile, isotonic solutions, storage at recommended temperatures, and avoidance of repeated freeze-thaw cycles to preserve peptide integrity. Analytical verification of peptide purity and activity is recommended for reproducibility in experimental protocols.

Future Research Directions
Ongoing research aims to further delineate the molecular mechanisms underlying angiotensin II-mediated pathophysiology and to identify novel therapeutic targets Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 61 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11466884